Nykode Reports the Completion of Patient Enrollment in P-II Trial of VB10.16 + Atezolizumab for the Treatment of Advanced Cervical Cancer

Published: Feb 11, 2022 | Tags: Nykode, VB10.16, Atezolizumab, P-II Trial, Advanced Cervical Cancer

GSK’s Benlysta (belimumab) Receives the NMPA’s Approval for the Treatment of Active Lupus Nephritis

Published: Feb 11, 2022 | Tags: GSK, Benlysta, belimumab, NMPA, Approval, Active Lupus Nephritis

Genentech Reports Results of Vabysmo and Susvimo in P-III (YOSEMITE/ RHINE/ Archway) Studies for the Treatment of DME & AMD

Published: Feb 11, 2022 | Tags: Genentech, Vabysmo, Susvimo, P-III, YOSEMITE/ RHINE/ Archway Studies, DME, AMD

Novavax Reports Results of NVX-CoV2373 in Pediatric Population of P-III (PREVENT-19) Trial for the Treatment of COVID-19

Published: Feb 11, 2022 | Tags: Novavax, NVX-CoV2373, Pediatric Population, P-III, PREVENT-19 Trial, COVID-19

Scynexis Reports Results of Ibrexafungerp in P-III (CANDLE) Study for the Prevention of Recurrent Vaginal Yeast Infections

Published: Feb 11, 2022 | Tags: Scynexis, Ibrexafungerp, P-III, CANDLE Study, Recurrent, Vaginal Yeast Infections

ObsEva Entered into a License Agreement with Theramex to Commercialize Linzagolix for Uterine Fibroids and Endometriosis -Associated Pain

Published: Feb 11, 2022 | Tags: ObsEva, Theramex, Linzagolix, Uterine Fibroids, Endometriosis

SaNOtize Reports Results of Nitric Oxide Nasal Spray in P-III Clinical Trial for the Treatment of COVID-19

Published: Feb 10, 2022 | Tags: SaNOtize, Nitric Oxide Nasal Spray, P-III Clinical Trial,  COVID-19

Eli Lilly Collaborated with Foundation Medicine to Develop FoundationOne CDx and FoundationOne Liquid CDx for Retevmo to Treat Cancer

Published: Feb 10, 2022 | Tags: Eli Lilly, Foundation Medicine, FoundationOne CDx, FoundationOne Liquid CDx, Retevmo Cancer

Regeneron Reports the US FDA Acceptance of sBLA for Priority Review of Dupixent (dupilumab) for the Treatment of Atopic Dermatitis

Published: Feb 10, 2022 | Tags: Regeneron, US, FDA, sBLA, Priority Review, Dupixent, dupilumab, Atopic Dermatitis

enGene Reports Preliminary Results of EG-70 in P-I/II (LEGEND) Trial for the Treatment of Non-Muscle Invasive Bladder Cancer

Published: Feb 10, 2022 | Tags: enGene, EG-70, P-I/II, LEGEND Trial, Non-Muscle Invasive Bladder Cancer

AKSO Entered into an Exclusive Collaboration with Huadong Medicine to Develop and Commercialize AB002 for Solid Tumors in Asia Pacific Ex-Japan.

Published: Feb 10, 2022 | Tags: AKSO, Huadong Medicine, AB002, Solid Tumors, Asia

AiCuris Entered into a WW License Agreement with Hybridize to Develop & Commercialize RNA-Based Therapy Against BK Virus

Published: Feb 10, 2022 | Tags: AiCuris, Hybridize, RNA-Based Therapy, BK Virus

Secura Bio Reports Completion of Enrollment in P-II (PRIMO) Study of Copiktra (duvelisib) for the Treatment of Peripheral T-cell Lymphoma

Published: Feb 09, 2022 | Tags: Secura Bio, P-II, PRIMO Study, Copiktra, duvelisib, Peripheral T-cell Lymphoma

EdiGene Collaborated with Neukio to Develop iPSC-NK Immune Cell Therapies for the Development of Solid Tumors

Published: Feb 09, 2022 | Tags: EdiGene, Neukio, iPSC-NK, Immune Cell Therapies, Solid Tumors

Bausch Health Launches Trulance (plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation in Canada

Published: Feb 09, 2022 | Tags: Bausch Health, Trulance, plecanatide, Health Canada, Approval, Irritable Bowel Syndrome, Constipation

Alkermes Reports Results of Lybalvi in P-IIIb (ENLIGHTEN-Early) Study for the Treatment of Schizophrenia or Bipolar I Disorder

Published: Feb 09, 2022 | Tags: Alkermes, Lybalvi, P-IIIb, ENLIGHTEN-Early Study, Schizophrenia, Bipolar I Disorder

Karyopharm Reports Results of Selinexor in P-III (SIENDO) Study for the Treatment of Advanced or Recurrent Endometrial Cancer.

Published: Feb 09, 2022 | Tags: Karyopharm, Selinexor, P-III, SIENDO Study, Endometrial Cancer

Healx Collaborated with Ovid to Develop and Commercialize Gaboxadol for Fragile X Syndrome

Published: Feb 09, 2022 | Tags: Healx, Ovid, Gaboxadol, Fragile X Syndrome

uniQure Reports First Patient Dosing of AMT-130 in P-Ib/II Trial for the Treatment of Huntington’s Disease

Published: Feb 08, 2022 | Tags: uniQure, AMT-130, P-Ib/II Trial, Huntington’s Disease

Sangamo Presents Updated Preliminary Results of ST-920 in P- I/II (STAAR) Study for Fabry Disease at WORLDSymposium 2022

Published: Feb 08, 2022 | Tags: Sangamo, ST-920, P- I/II, STAAR Study, Fabry Disease, WORLDSymposium, 2022

NGM Bio’s NGM621 Receives the US FDA’s Fast Track Designation for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

Published: Feb 08, 2022 | Tags: NGM Bio, NGM621, US, FDA, Fast Track Designation, Geographic Atrophy, Age-Related Macular Degeneration

Actuate Therapeutics Initiates Randomized Trial of Elraglusib + Folfirinox as 1L Treatment of Advanced Pancreatic Cancer

Published: Feb 08, 2022 | Tags: Actuate Therapeutics, Elraglusib, Folfirinox, Advanced, Pancreatic Cancer

RedHill Biopharma Reports Results of Opaganib in P-II/III Study for the Treatment of Severe COVID-19

Published: Feb 08, 2022 | Tags: RedHill Biopharma, Opaganib, P-II/III Study, Severe COVID-19

Astellas Presents Results of AT845 in P-I/II (FORTIS) Trial for Late-Onset Pompe Disease (LOPD) at WORLDSymposium 2022

Published: Feb 08, 2022 | Tags: Astellas, AT845, P-I/II, FORTIS Trial, Late-Onset Pompe Disease, WORLDSymposium 2022

Active Biotech Reports First Patient Dosing in the P-Ib/IIa Study of Tasquinimod for the Treatment of Multiple Myeloma

Published: Feb 07, 2022 | Tags: Active Biotech, P-Ib/IIa Study, Tasquinimod, Multiple Myeloma

BioMarin Presents 2-Year Analysis of Valoctocogene Roxaparvovec in P-III (GENEr8-1) Study for Severe Hemophilia A at EAHAD 2022

Published: Feb 07, 2022 | Tags: BioMarin, Valoctocogene Roxaparvovec, P-III, GENEr8-1 Study, Severe Hemophilia A, EAHAD 2022

Pfizer and Valneva Report Results of VLA15 in P-II Study for the Treatment of Lyme Disease

Published: Feb 07, 2022 | Tags: Pfizer, Valneva, VLA15, P-II Study, Lyme Disease

Cytokinetics Receives the US FDA Acceptance of NDA for Omecamtiv Mecarbil to Treat Heart Failure with Reduced Ejection Fraction

Published: Feb 07, 2022 | Tags: Cytokinetics, US, FDA, NDA, Omecamtiv Mecarbil, Heart Failure, Reduced, Ejection Fraction

CSL Behring Presents Results of Etranacogene Dezaparvovec in P-III (HOPE-B) Trial for the Treatment of Hemophilia B at EAHAD 2022

Published: Feb 07, 2022 | Tags: CSL Behring, Etranacogene Dezaparvovec, P-III, HOPE-B Trial, Hemophilia B, EAHAD 2022

Sanofi’s Enjaymo (sutimlimab-jome) Receives the US FDA’s Approval for the Treatment of Cold Agglutinin Disease

Published: Feb 07, 2022 | Tags: Sanofi, Enjaymo, sutimlimab-jome, US, FDA, Approval, Cold Agglutinin Disease

Related Post: PharmaShots Weekly Snapshots (January 31 – February 04, 2022)